Genomics plc has reported significant, positive results from the world’s first pilot investigating the use of genomic polygenic risk score testing to support the prevention of cardiovascular disease (CVD) in NHS clinical practice, at the American Heart Association Scientific Sessions today.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery